As the primary component of the amyloid plaques seen in the brains of Alzheimer patients, amyloid- (A) refers to peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease. The amyloid precursor protein (APP), which is cut by specific enzymes to produce A, produces the peptides. Amyloid molecules can group together to create a variety of flexible, soluble oligomers.A amyloid-peptide buildup results from excessive A production or malfunctioning clearance mechanisms. Amyloid- forms diffuse and neuritic plaques in the parenchyma and blood vessels by self-aggregating into oligomers of various sizes. Strong synaptotoxins, proteasome inhibition, mitochondrial inhibition, alteration of intracellular Ca2+ levels, and induction of inflammatory processes are all characteristics of amyloid-oligomers and plaques. Neuronal dysfunction is also thought to be influenced by the loss of A's typical physiological functions.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V121819 | (Gln22)β-Amyloid (1-40) human TFA | (Gln22)β-Amyloid (1-40) human TFA is a peptide containing amyloid β protein (Aβ) used in Alzheimer's disease research. | |
|
V121833 | (Mor-Cor)Ag(III) | (Mor-Cor)Ag(III) is a silver(III) porphyrin complex that can penetrate the blood-brain barrier. | |
|
V71438 | 2,3-Dehydrosilybin A | 25166-14-7 | 2,3-Dehydrosilybin A is a longevity-promoting and anti-aggregation compound. |
|
V71371 | 2-Hydroxy-5-(phenyldiazenyl)benzoic acid-d5 | 1331662-16-8 | 2-Hydroxy-5-(phenyldiazenyl)benzoic acid-d5 is deuterated labeled 2-Hydroxy-5-(phenyldiazenyl)benzoic acid. |
|
V104737 | 2002-G12 | 313666-93-2 | 2002-G12 (compound 5a) is an Aβ42 inhibitor that can reduce Aβ42 toxicity by 76%. |
|
V111853 | 4-Sulfocalix[4]arene | 112269-92-8 | 4-Sulfocalix[4]arene (p-sulfonocalix[n]arene) is an amyloid β42 (amyloid β42) binder with a Kd value of 5.39 M. |
|
V126972 | 5-FAM-β-Amyloid (1-28) | 5-FAM-β-Amyloid (1-28) is a fluorescently labeled β-amyloid protein (1-28). | |
|
V77650 | 5-FAM-β-Amyloid (1-42), human TFA (5-FAM-Amyloid β-peptide (1-42) (human) TFA) | 5-FAM-β-Amyloid (1-42), human (5-FAM-Amyloid β-peptide (1-42) (human) TFA is a 5-FAM-labeled β-Amyloid (1-42), human (TFA). | |
|
V126973 | 5-FAM-β-Amyloid (1-42), human Tris | 5-FAM-β-Amyloid (1-42), human Tris is a 5-FAM-labeled β-amyloid protein (1-42), human TFA. | |
|
V86199 | 5-FAM-β-Amyloid (1-42), human Tris (5-FAM-Amyloid β-peptide (1-42) (human) Tris) | ||
|
V83543 | 6′-Methyl paeonol | 6540-66-5 | |
|
V71443 | 7-Deoxy-trans-dihydronarciclasine | 145987-74-2 | 7-Deoxy-trans-dihydronarciclasine is an alkaloid and an inhibitor (blocker/antagonist) of tobacco mosaic virus (TMV) (IC50= 1.80 μM). |
|
V71439 | [Ala28]-β Amyloid(25-35) (β(25-35)KA) | 173993-86-7 | [Ala28]-β Amyloid(25-35) (β(25-35)KA) is an electroneutral mutant peptide of Aβ(25-35) that accelerates the aggregation of firefly luciferase. |
|
V114718 | [Ala28]-β Amyloid(25-35) TFA | [Ala28]-β amyloid(25-35) (β(25-35)KA) TFA is an electronegative mutant peptide of Aβ(25-35) that can accelerate the aggregation of firefly luciferase. | |
|
V71378 | [Arg6]-β-Amyloid (1-40), england mutation | 1802084-26-9 | [Arg6]-β-Amyloid (1-40), england mutation is a biologically active peptide. |
|
V77472 | [Arg6]-β-Amyloid (1-42), england mutation | [Arg6]-β-Amyloid (1-42), england mutation is a biologically active peptide. | |
|
V71392 | [Asn23] β-Amyloid (1-40), Iowa mutation | 374796-72-2 | [Asn23] β-Amyloid (1-40), Iowa mutation is a biologically active peptide. |
|
V77473 | [Asn23]-beta-Amyloid (1-42), iowa mutation | [Asn23]-beta-Amyloid (1-42), iowa mutation is a biologically active peptide. | |
|
V92286 | [D-Ser14]-Humanin | 570382-85-3 | [D-Ser14]-Humanin is a biologically active peptide in which the Ser14 residue of humanin is changed from L-form to D-form. |
|
V113880 | AAKLVFF | 1038400-67-7 | AAKLVFF is an oligopeptide that can self-assemble into nanotubes. |